HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Supplemental Figure All Versions of this Article: 291/6/R1657    most recent 00010.2006v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (9) Citing Articles via Google Scholar Google Scholar Articles by Choi, E.-H. Articles by Feingold, K. R. Search for Related Content PubMed PubMed Citation Articles by Choi, E.-H. Articles by Feingold, K. R.

INFLAMMATION AND CYTOKINES

Glucocorticoid blockade reverses psychological stress-induced abnormalities in epidermal structure and function

¹Dermatology and Medical Services (Metabolism), Veteran Affairs Medical Center San Francisco and Department of Dermatology and Medicine, University of California San Francisco, San Francisco, California; and ²Department of Dermatology, Yonsei University, Wonju College of Medicine, Wonju, Korea

Submitted 5 January 2006 ; accepted in final form 17 July 2006

Many cutaneous disorders are adversely affected by psychological stress (PS), but the responsible mechanisms are poorly understood. Recent studies have demonstrated that PS decreases epidermal proliferation and differentiation, impairs permeability barrier homeostasis, and decreases stratum corneum integrity. PS also increases the production of endogenous glucocorticoids (GC), and both systemic and topical GC cause adverse effects on epidermal structure and function similar to those observed with PS. We therefore hypothesized that increased endogenous GC in PS mediates its adverse cutaneous effects. To test this hypothesis, we used two independent approaches, administering either RU-486, a GC receptor antagonist that inhibits GC action, or antalarmin, a corticotropin-releasing hormone (CRH) receptor antagonist that prevents increased GC production in the face of PS. Inhibition of either GC action or production prevents the PS-induced decline in epidermal cell proliferation and differentiation, impairment in permeability barrier homeostasis, and decrease in stratum corneum (SC) integrity. Moreover, the pathophysiological basis for the abnormality in permeability barrier homeostasis; i.e., decreased lamellar body production and secretion, is restored toward normal by inhibition of GC action. Similarly, the mechanistic basis for the decrease in SC integrity, i.e., a reduction in corneodesmosomes, is also normalized by inhibition of GC action. Thus many of the adverse effects of PS on epidermal structure and function can be attributed to increased endogenous GC and conversely, approaches that either reduce GC production or action might benefit cutaneous disorders that are provoked or exacerbated by PS.

RU-486; corticotropin-releasing hormone; stratum corneum integrity; barrier homeostasis

This article has been cited by other articles:

				K. R. Feingold Thematic review series: Skin Lipids. The role of epidermal lipids in cutaneous permeability barrier homeostasis J. Lipid Res., December 1, 2007; 48(12): 2531 - 2546. [Abstract] [Full Text] [PDF]